|Table of Contents|

The study of serum matrix metalloproteinase-9 and its inhibitor and the efficacy of Shenyi capsule combined with chemotherapy in the treatment of advanced NSCLC

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 06
Page:
896-901
Research Field:
Publishing date:

Info

Title:
The study of serum matrix metalloproteinase-9 and its inhibitor and the efficacy of Shenyi capsule combined with chemotherapy in the treatment of advanced NSCLC
Author(s):
Wang Guohua1; Liu Fengling2; Zhang Zhenshan1; Li Jinhong1; Liu Fei1; Jiang Yue1; Zhao Enfeng1
1.Department of Oncology,Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine,Hebei Cangzhou 061001,China;2.Department of Oncology,The Fourth Hospital of Hebei Medical University,Hebei Shijiazhuang 050011,China.
Keywords:
non small cell lung cancer; Shenyi capsule; curative effect; cathepsin-1 inhibitor; matrix metalloproteinase-9
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2017.06.015
Abstract:
Objective:To study Shenyi capsule combined with chemotherapy and chemotherapy alone on advanced IIIb / IV non small cell lung cancer (NSCLC) and effect on serum MMP-9 and TIMP-1 levels.Methods：Patients were randomly assigned to Shenyi capsule plus chemotherapy group and chemotherapy group.Chemotherapy include：Pacilitaxel 175mg／m2,ivdrip d1，Cisplatin 75mg／m2,ivdrip divided into 3 or 4 days for a period of 21 days,Pemetrexed 500mg／m2,ivdrip dl,Cisplatin 75mg／m2,ivdrip divided into 3 or 4 days with a 21-day cycle,Gemcitabine 1 000mg／m2,ivdrip d1，8,Cisplatin 75mg／m2,ivdrip divided into 3 or 4 days with a 21-day cycle,NP(Vinorelbine 25mg／m2,ivdrip d1，8,Cisplatin 75mg／m2,ivdrip divided into 3 or 4 days with a 21-day cycle).Shenyi capsule each oral 20mg,bid,at least 6 weeks.To detect serum MMP-9 and TIMP-1 level before chemotherapy and after the two course of chemotherapy using ELISA method.Results：Total of 45 patients in Shenyi capsule group,44 cases in hemotherapy group.The two groups did not appear completely remission.Capsule plus chemotherapy group,PR 20(44.4％),SD 17(37.8％),PD 8(17.8％)with RR 20(44.4％)and clinical benefit 82.2％,in chemotherapy group,PR 16(36.4％),SD 11(25.0％),PD 17(38.6％)with RR 16(36.4％)and clinical benefit 61.4％（P＞0.05).Disease control had a significant difference (P＜0.05).Comparison of CR+PR,SD,PD in all patients before treatment,serum MMP-9,TIMP-1 levels,there was no significant difference (P＞0.05).After treatment，there was a significant difference(P＜0.05),an increasing trend with the effect lowering.Compared two groups before treatment and after treatment two times the level of serum MMP-9,Shenyi capsule and a combined chemotherapy group decreased more significantly,the difference was significant (P＜0.05),while no significant difference of serum TIMP-1 level (P＞0.05).The relationship between patients with other features and MMP-9,TIMP-1 levels:the levels of MMP-9 in patients with stage IV than patients with stage IIIb in peripheral blood were significantly increased,the difference was significant (P＜0.05).But the peripheral serum TIMP-1 in IIIb phase and IV phase had no significant difference.Age,gender,ECOG,pathology,significant differences were not found in MMP-9,TIMP-1 levels.Common side effects and QOL (quality of life,QOL) observation:the observation group (Shenyi capsule combined with chemotherapy group) in the gastrointestinal tract reaction (such as nausea,vomiting,abdominal distension), bone marrow suppression (such as leukopenia,anemia,thrombocytopenia) were lower than control group reduce (P＜0.05),the observation group in improving the quality of life was also significantly higher than that of the control group(P＜0.05).Conclusion：Shenyi capsule combined with chemotherapy peripheral serum MMP-9 level decreased more significantly,and there is significant difference,but there is no significant difference between the changes of serum TIMP-1 level.Serum MMP-9,TIMP-1 levels after treatment with reduced efficacy showed a rising trend,therefore it can be used as a reference index to judge the curative effect.

References:

［1］Li YL,Gao H,Wang X,et al.The relationship between Kiss-1,Kiss-1 receptor GPR54 and matrix metalloproteinase-9 and the invasion and metastasis of non small cell lung cancer［J］.Modern Oncology,2011,19(8):1145-1146.［李银玲，高辉，王鑫，等.Kiss-1、Kiss-1受体GPR54及基质金属蛋白酶-9与非小细胞肺癌侵袭转移的关系［J］.现代肿瘤医学，2011,19（8）：1145-1146.］
［2］Zhao J,Tan YM,Zhang XZ,et al.Clinical significance of determination of matrix metalloproteinase in non small cell lung cancer［J］.Clin Rational Use Drugs,2010,3(12):16-17.［赵静，谭泳梅，张兴展，等.非小细胞肺癌血清中基质金属蛋白酶含量测定的临床意义［J］.临床合理用药杂志，2010，3（12）：16-17.］
［3］Jung KK，Liu XW，Chirco R，et al．Identification of CD63 as a tissue inhibit or of metallopmteinase-1 interacting cell surface protein ［J］．EMBO J，2006，25(17)：3934-3942.
［4］Hou JJ,Song YQ,Kang LH,et al.Adjuvant therapy effect of 20(R)-ginseng saponin Rg3 in the aged of elderly cancer patients with radiotherapy and chemotherapy［J］.Chin J Gerontol,2011,31(20):4024-4025.［侯俊杰，宋艳秋，康丽花，等.20（R）-人参皂甙Rg3对老年肿瘤患者放、化疗后的辅助治疗效果［J］.中国中老年杂志，2011，31（20）：4024-4025.］
［5］Qian LL.Inhibitory effect of ginsenoside Rg3 on breast cancer cells［D］.Hangzhou:Zhejiang University of Technology,2010.［钱伶凌.人参皂甙Rg3对乳腺癌细胞的抑制作用［D］.杭州：浙江工业大学，2010.］
［6］Xin Y,Jiang X,Cui JS,et al.Study on the inhibition of angiogenesis and the mechanism of Rg3 in the formation of new blood vessels of B16 melanoma ［J］.Chin J Cancer Prevention Control,2010,17 (08):590-593.［辛颖，姜新，崔俊生，等.人参皂甙Rg3抑制B16黑色素瘤新生血管生成及其机制的探讨［J］.中华肿瘤防治杂志，2010，17(08):590-593.］
［7］He JB,Zhang YQ,Xiang Z.Effects of Sura and ginsenoside Rg3 on the growth of transplanted tumor in mice［J］.Tianjin Med,2013,41(9):887-890.［贺兼斌，张贻秋，向志.苏拉明联合人参皂苷Rg3抑制肺腺癌小鼠移植瘤生长的作用［J］.天津医药，2013,41(9)：887-890.］
［8］Rao YQ,Liu XE,Wang TX.Effect of ginsenoside Rg3 on the proliferation of lung cancer NCI-H1650 cells［J］.J Oncol,2013,19(6):413-416.［饶远权，刘杏娥，王廷祥.人参皂苷Rg3抑制肺癌NCI-H1650细胞增殖作用研究［J］.肿瘤学杂志，2013,19(6):413-416.］
［9］Zhang YM,Wang JX.Effects of ginsenoside Rg3 on the proliferation of Lewis lung cancer cells in vitro and immune function in tumor bearing mice［J］.Practical Clin Med J,2014,18(1):5-8.［张玉梅，王家晓，等.人参皂甙Rg3对Lewis肺癌细胞体外增殖及荷瘤小鼠免疫功能的影响［J］.实用临床医药杂志，2014,18(1):5-8.］
［10］He JB,Liao HZ,Yi GZ,et al.Effect of ginsenoside Rg3 on the expression of somatostatin receptor in mouse lung adenocarcinoma［J］.Cancer,2012,32(8):572-577.［贺兼斌，廖慧中，易高众，等.人参皂苷Rg3对小鼠肺腺癌移植瘤生长抑素受体表达的调控及意义［J］.肿瘤，2012,32(8):572-577.］
［11］He JB,Liao HZ,Zhang YQ.The effect and mechanism of Sura combined with ginsenoside Rg3 on the inhibition of tumor metastasis in mice［J］.Chin J Modern Med,2013,23(21):28-34.［贺兼斌，廖慧中，张贻秋.苏拉明联合人参皂苷 Rg3 抑制肺腺癌小鼠移植瘤转移的作用及机制［J］.中国现代医学杂志，2013,23(21):28-34.］
［12］Dong LZ,Wu ZM,Zhu Z,et al.Study on the inhibition of lung cancer growth by ERK pathway in Lewis mice by ginsenoside Rg3［J］.J Med University Tianjin,2014,20(4):271-274.［董莉真，吴志敏，朱泽，等.人参皂苷Rg3调控ERK通路抑制Lewis小鼠肺癌生长的研究［J］.天津医科大学学报，2014,20(4):271-274.］
［13］Ma LJ.Rg3 induced apoptosis of MCF-7 cells induced by Fas in breast cancer cells［D］.Taiyuan:Shanxi Medical University,2010.［马利军.人参皂甙Rg3上调Fas蛋白诱导乳腺癌MCF-7细胞的凋亡［D］.太原：山西医科大学，2010.］
［14］Ke SZ,Liu Y,Jin HJ,et al.Mechanism of ginsenoside Rg3 against Lewis lung cancer in mice［J］.J Immunol,2012,28(05):389-393.［柯仕忠，刘瑶，金浩杰，等.人参皂甙Rg3抗小鼠Lewis肺癌的机制研究［J］.免疫学杂志，2012，28(05):389-393.］
［15］An N,Zhu W.Research progress of anti tumor effect mechanism of ginsenoside Rg3［J］.Modern Oncology,2008,16(4):648-652.［安宁，朱文.人参皂苷Rg3抗肿瘤作用机制研究进展［J］.现代肿瘤医学,2008,16(4):648-652.］
［16］Chen YL.Antitumor effect of Rg3 combined with 5-fluorouracil in the tumor bearing mice［J］.Chin J Modern Med,2012,22 (19):29-31.［陈亚林.人参皂甙Rg3联合5-氟尿嘧啶对肝癌荷瘤小鼠的抑瘤作用［J］.中国现代医学杂志,2012,22(19):29-31.］
［17］Xu XH,He JB,Zhang P.Effect and its mechanism of ginsenoside Rg3 and Sura on the growth of lung cancer in mice［J］.Chin J Cancer Prevention and Control,2013，2:97-101.［许霞辉，贺兼斌，张平.人参皂苷Rg3联合苏拉明对小鼠肺癌生长影响及其机制的探讨［J］.中华肿瘤防治杂志，2013，2:97-101.］
［18］Chen DF,Zhuang YJ,Huang JQ.Efficacy of ginsenoside Rg3 combined with FOLFOX4 regimen in the treatment of rectal cancer［J］.Clin Oncol J,2013，2:163-165.［陈大富，庄永敬，黄建强.人参皂甙Rg3联合FOLFOX4方案治疗直肠癌的疗效观察［J］.临床肿瘤学杂志,2013，2:163-165.］
［19］Wang X,Li Y.Research progress on the inhibition effect of Chinese herbs on gastric cancer ［J］.Jilin Traditional Chin Med,2012,9:963-966.［王鑫，李勇.人参类中药对胃癌抑制作用的研究进展［J］.吉林中医药,2012,9:963-966.］
［20］Yu XT,Wang SP.Clinical observation on the treatment of postoperative patients with gastric cancer after treatment with ginsenoside Rg3 combined with chemotherapy［J］.Chin J Cancer Prevention and Control,2010,10:779-781.［于学涛，王淑萍.人参皂苷Rg3联合化疗治疗对胃癌术后患者的临床观察［J］.中华肿瘤防治杂志，2010,10:779-781.］
［21］Zhang XP,Ma DL,Chen XM.Research progress on antitumor and mechanism of ginsenoside Rg3［J］.Chin Licensed Pharmacist,2012,9(11):52-56.［张晓平，马大龙，陈新梅.人参皂苷Rg3抗肿瘤及其作用机制研究进展［J］.中国执业药师，2012，9(11):52-56.］

Memo

Memo:
-
Last Update: 2017-01-26